Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescriptions Generated Since Inception of RxConnect
Adzenys XR-ODT Total Prescription (TRx) Unit Growth Driven by a Combination of Continued Sales Force Execution, Leveraging of the Aytu RxConnect Patient Support Program, and a Positive Response to the Adderall® XR Supply DisruptionAdzenys XR-ODT is …
Adzenys XR-ODT Total Prescription (TRx) Unit Growth Driven by a Combination of Continued Sales Force Execution, Leveraging of the Aytu RxConnect Patient Support Program, and a Positive Response to the Adderall® XR Supply Disruption
Adzenys XR-ODT is the Only FDA-Approved, Extended-Release, Orally Disintegrating Tablet Formulation of Amphetamine
Adzenys XR-ODT Continues to be Available as an FDA-Approved Bioequivalent Alternative to Adderall XR
ENGLEWOOD, CO / ACCESSWIRE / November 30, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced the highest weekly prescription total for Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets, CII, since the inception of the Aytu RxConnect patient support program.
For the week ending November 18, 2022, a record 5,186 total prescriptions were filled for Adzenys XR-ODT. Adzenys XR-ODT prescriptions are up 9.9% over the preceding thirteen-week period.
Adzenys XR-ODT has a twelve-hour duration of action, has been FDA-approved as bioequivalent to Adderall® XR, and is available in six equivalent strengths as follows:
Josh Disbrow, Chief Executive Officer of Aytu, said, "We're pleased with the continuing growth of Adzenys XR-ODT, driven in part through our sales team's execution in the field and our messaging to clinicians. Specifically, we continue to inform our clinician partners that Adzenys XR-ODT, an FDA-approved bioequivalent alternative to Adderall XR, continues to be available for their patients. Given the continuing supply disruptions many patients and clinicians have faced this fall and may face into 2023, we're pleased to offer Adzenys XR-ODT as a potential alternative to Adderall XR. Access to Adzenys XR-ODT is simple, convenient, and cost effective for patients via the Aytu RxConnect program and our network of approximately 1,000 pharmacies nationwide."